Neurological Surgery, P.C. Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2008
NCT00848523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

The Long Island Brain Tumor Center at Neurological Surgery, P.C.

Active Ingredients

Drugs in Phase 2 Trials (3)

bevacizumab (avastin) (1 trial)

panobinostat (farydak) (1 trial)

tpi-287 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3